Introduction
The tumor suppressor p53 is a tetrameric sequencespeci®c transcriptional activator that is negatively regulated by the adenoviral protein E1B and the MDM2 protein (for a review see reference (Levine, 1997) . P53 or its regulators p19ARF and MDM2 are mutated in most of all human cancers. The tumor suppressor eect of the p53 pathway is mainly linked to the capability of p53 to induce cell cycle arrest or apoptosis (Levine, 1997) . The growth inhibitory eects of p53 are mediated by p53-dependent upregulation of the cyclin-dependent kinase inhibitor p21/WAF1/cip1 (el Deiry et al., 1993; Harper et al., 1993; Xiong et al., 1993) . As a consequence of p21-dependent inhibition of G1-cyclin/CDK complexes, the phosphorylation of the retinoblastoma (RB) protein is blocked (Slebos et al., 1994) thereby preserving its association with histone acetylase and E2F transcription factors which in turn blocks cells from exiting G1 phase (Sherr and Weber, 2000) .
P53-induced apoptosis can depend on the transcriptional regulation of apoptosis-related genes but can also occur independent of transactivation, as in some models of p53-dependent apoptosis inhibition of protein translation or expression of transactivation de®cient p53 mutants does not interfere with the apoptotic response (Caelles et al., 1994; Wagner et al., 1994; Yan et al., 1997; Haupt et al., 1995) . Among the numerous list of p53-inducible gene products are several with a well-de®ned role in apoptosis, such as Bax (Miyashita and Reed, 1995) , Fas/Apo1 (Muller et al., 1998) and TRAIL-R2 1 /DR5/Killer (Wu et al., 1997) . As in de®ned models each of these proteins has been shown to act as an essential component of the p53-dependent apoptotic response, none of them can be regarded as a single critical eector of p53-dependent cell death. For example, p53 stimulates Fas synthesis by p53 binding elements in the promoter and ®rst intron of the Fas gene (Owen-Schaub et al., 1995; Muller et al., 1998) and, in addition, activates the transport of Fas stored in the Golgi to the cell membrane (Bennett et al., 1998) . Nevertheless, in mice with a de®cient Fas gene, p53-dependent apoptosis of irradiated thymocytes is not signi®cantly aected (Reinke and Lozano, 1997) . Thus, the regulation of a cell type-speci®c subsets of apoptosis-related genes seems to be sucient for p53 transactivation-dependent apoptosis.
In principle, activation of the apoptotic program also may rely on or, at least, be supported by the inhibition of anti-apoptotic mechanisms. In this context, some recent reports have shown that the anti-apoptotic NF-kB pathway can have opposite roles in p53-dependent apoptosis. In one study, p53 and aspirin, known to inhibit NF-kB activation, were shown to synergistically induce cell death (Shao et al., 2000) . In accordance with these data, it has been shown that activation of the NF-kB pathway functionally inactivates p53 (Pise-Masison et al., 2000) . In another study, however, the loss of NF-kB activity abrogated p53-induced cell death (Ryan et al., 2000) .
To get deeper insight into the molecular mechanisms of p53 transactivation-dependent apoptosis, we analysed DLD-1 cells with endogenous mutant p53 alleles that allow the inducible expression of p53-wt or p53-R175A, the latter lacking the transactivation capacities of the wildtype protein. We found that in this particular system p53-induced apoptosis is independent from activation of caspase-8, but rather occurs as a consequence of shifting the ratio of pro-and antiapoptotic bcl-2 family members towards the proapoptotic ones, allowing activation of caspase-9. Moreover, p53-dependent apoptosis seems to be independent of NF-kB activation in this tumor cell line.
Results
Caspase-9 and caspase-3, but not caspase-8, are activated in p53-induced cell death
To gain deeper insight into the mechanisms of p53-mediated apoptosis, we analysed DLD-1 cells carrying mutations in their endogenous p53 alleles (S241F; Rodrigues et al., 1990) but are stably transfected with p53-wt and p53-R175H, respectively, under control of an inducible doxycycline-regulated promoter (Yu et al., 1999) . Upon removal of doxycycline, the expression of p53 was already signi®cantly induced in both cell lines after 3 h (Figure 1a,b) . The p53 and p53-mut175 expression levels induced by doxycycline removal, exceeded the endogenous protein levels many times (Figure 1a,b) . Thus, a putative dominant-negative eect of endogenous mutated p53 on induced p53-wt should be negligible. As shown elsewhere (Yu et al., 1999) , only p53-wt, but not p-53-R175H induced cell death and expression of p21 in DLD-1 cells ( Figure  1a ). p53-induced cell death, but not p53-induced cell cycle arrest, was blocked by 100 mM of the broad range caspase inhibitor z-VAD-fmk, indicating an essential involvement of this kind of proteases in this model of p53-dependent cell death ( Figure 1c ). Next we analysed the p53-mediated activation of caspases by Western blotting. First signs of processed, i.e. activated, caspase-9, the initiator caspase of the mitochondria-dependent apoptotic pathway, and caspase-3, the central executioner caspase, were found 12 h after induction of p53 (Figure 2a ). In accordance with the kinetics of caspase activation, we found by microscopic inspection that the ®rst dead cells appear after 12 ± 18 h, and 36 ± 48 h upon p53-wt induction more than 90% of the cells were killed (data not shown). There was no evidence for the activation of caspase-8 in this model of p53-induced apoptosis (Figure 2a ) indicating that death receptor activation was not crucially involved (Varfolomeev et al., 1998) . Nevertheless, both TRAIL and FasL were capable to induce cell death and caspase-8 activation in the absence of p53-induction (Figure 2b ), indicating that the apoptotic death receptor pathway was functional in DLD-1 cells.
Transcriptional regulation of apoptosis-related genes by p53 in DLD-1 cells
The capability of p53 for sequence-speci®c transactivation, being lost in the hot-spot R175H mutant, is essential for the initiation of the apoptotic process in DLD-1 cells (Yu et al., 1999) . We therefore systematically analysed steady state mRNA-level of about 60 Figure 1 p53-wt, but not p53-R175H, induces caspase-dependent cell death in DLD-1 cells. (a,b) Inducible expression of p53-wt and p53-R175H. DLD-1 cells were induced by omitting doxycycline from the culture medium for the indicated times. Cells were then analysed for p53 expression by RPA analysis (a) and Western blotting (b) Inducible expression of p53-wt, but not of p53-R175H, resulted in induction of p21 (a). (c) Cells were allowed to express p53-wt and p53-R175H, respectively, for 24 h in the presence or absence of the indicated concentrations of z-VAD-fmk and were subsequently assayed for cell viability by crystal violet staining apoptosis-related genes by means of RNAse protection assays. RNAs were isolated 3, 6, 9, or 12 h after p53-induction. Hence, under these conditions caspases were not active yet (0 ± 9 h) or caspase activation had just started (12 h). We found that approximately 15% of the investigated apoptosis-related genes were signi®-cantly regulated by p53 (Table 1 and Figure 3 ). This portion of p53-regulated genes ± when focused on apoptosis-related genes ± was signi®cantly higher compared to other studies where, unselected sets of genes had been screened. For example, by analysis of more than 6000 genes using an oligonucleotide microarray, less than 3% were found to be p53-regulated (Zhao et al., 2000) . The death receptors Fas/ Apo1 and TRAIL-R2 have been recently identi®ed as transcriptional targets of p53 (Muller et al., 1998; Wu et al., 1997) . Although death receptors seemed not to be involved in p53-induced apoptosis in DLD-1 cells, a 3 ± 4-fold upregulation of TRAIL-R2-and Fas-mRNA was detectable upon induction of p53, but not upon induction of p53-R175H (Figure 3a) . Moreover, the death receptor TRAIL-R1 was induced by p53-wt, too ( Figure 3a) . Remarkably, the expression levels of almost all investigated members of the bcl2-family were regulated by p53-wt. Proapoptotic members (Bik, Bak) was up-regulated, whereas an anti-apoptotic member (Bcl-x L ) was repressed in response to p53-induction ( Figure 3b ). Again, a signi®cant transcriptional regulation was never found upon induction of p53-R175H. The p53-induced shift of the ratio of proand anti-apoptotic bcl2-family members towards the pro-apoptotic molecules is in good accordance with the mitochondria-dependent mode of p53-induced apoptosis observed before. So far, the observed transcriptional regulation of p53 target genes matched well to a common principle, in which pro-apoptotic factors were upregulated and anti-apoptotic factors were repressed. However, we found a remarkable exception of this theme, namely cFLIP.
FLIP (FLICE-inhibitory protein) (Irmler et al., 1997) , also termed CASH (Goltsev et al., 1997) , Casper (Shu et al., 1997) ; CLARP (Inohara et al., 1997) , FLAME-1 (Srinivasula et al., 1997) , I-FLICE , MRIT (Han et al., 1997) and Usurpin (Rasper et al., 1998) , has recently been identi®ed as a FADD-binding inhibitor of death receptor-induced apoptosis. FLIP exist in two splice forms, FLIPlong and FLIPshort, whereby FLIPlong is structurally related to caspase-8. Hence, FLIPlong consists of two N-terminal death eector domains (DED) and a Cterminal caspase-like domain with a tyrosine instead of a cysteine in the active site. FLIP has therefore no caspase activity. FLIPshort corresponds to the DEDs of FLIPlong. p53-induced upregulation of FLIPmRNA in DLD-1 cells ( Figure 3c ) was paralleled by an elevated level of FLIP protein. Moreover, the Western blot analysis showed that FLIPshort rather than FLIPlong was upregulated (Figure 4a ). To further Figure 2 Activation of caspases during p53-wt-and death receptor-induced apoptosis. (a) After induction of p53-wt for the indicated times the cells were lysed in RIPA buer. Proteins were immunoblotted with antibodies speci®c for caspase-2, -3, -8 and -9 to detect cleavage of these caspases which is indicative for activation of these enzymes. (b) DLD-1 cells were treated for 3 h with TRAIL and FasL, respectively, lysed in RIPA buer and assayed by immunoblotting for caspase-8 processing RNase protection assay analyses of steady state mRNA ± levels of various apoptosis-related genes after induction of p53-wt and p53-R175H. Expression of p54-wt and p53-R175H was induced for the indicated times and total RNAs were isolated for RPA analysis. Ten mg of each RNA sample was analysed with the hApo3c (a), hApo-2 (b), hApo-6 (b) and hApo-3b (c) MultiProbe template sets to detect the indicated mRNAs. L32 and GAPDH were included in each template set as internal controls.
Relative induction-values were calculated as described in Materials and methods HEK293 cells whereas a p53-mutant lacking the capability of sequence-speci®c transactivation, had no eect on reporter gene activity (Figure 4c ). In accordance, after removal of doxycycline, the FLIP- promoter reporter gene construct was induced in DLD-1-p53wt-but not in DLD-1-p53mut cells (Figure 4d ). Induction of p53 for 6 or 9 h had no signi®cant eect on TRAIL-and FasL-induced apoptosis (data not shown), suggesting that the extent of p53-dependent FLIP-induction was not sucient to interfere with death receptor-induced apoptosis in this particular cellular system.
p53-wt but not p53-R175H inhibits TNF-mediated NF-kB activation
There is some controversy about the interplay of p53 and NF-kB activation in the induction of p53-mediated cell death (Webster and Perkins, 1999; Ryan et al., 2000; Pise-Masison et al., 2000) . We have analysed the eect of p53 on TNF-induced NF-kB activation to clarify the relationship between p53 and NF-kB in DLD-1 cells. Upon induction of p53-wt we found no evidence for NF-kB activation, neither in terms of translocation (Figure 5a ), nor in terms of activation of a NF-kB driven reporter gene ( Figure 5b , open bars). However, TNF-induced NF-kB activation was easily detectable by EMSA analysis (Figure 5a ), by activation of a NF-kB driven reporter gene (Figure 5b , ®lled bars) as well as by synthesis of the NF-kB-dependent gene product cIAP2 (Figure 5c ). Interestingly, TNF-induced production of NF-kB-regulated gene products (reporter gene in Figure 5b , cIAP2 in Figure 5c ) was almost completely abrogated in p53-wt but not in p53-R175H expressing cells (Figure 5b,c) . NF-kB inhibition by p53 was most likely mediated downstream of the activation of the IKK complex as TNF-induced I-kB degradation (data not shown) and NF-kB translocation measured by EMSA analysis (Figure 5d ) were not signi®cantly aected by p53 over a wide range of TNF concentrations, whereas in side by side-performed reporter gene assays the TNF-induced transcription of NF-kB driven reporter gene was drastically reduced (Figure 5e ). It has been recently shown that NF-kB activation can be shut down by caspases via cleavage of components of the NF-kB pathway during ongoing apoptosis (Levkau et al., 1999; Lin et al., 1999; Irmler et al., 2000; Reuther and Baldwin, 1999) . We therefore checked whether the p53-mediated inhibition of TNF-induced NF-kB activation was dependent on the concomitant activation of the apoptotic program. This was not the case, as in the presence of z-VAD-fmk p53-dependent apoptosis was blocked whereas TNF-induced NF-kB activation was still inhibited (data not shown).
Discussion
Although p53 transcriptionally upregulates at least three death domain-containing receptors, namely Fas, TRAIL-R1 and TRAIL-R2 (Figure 3 ), these receptors do not signi®cantly contribute to p53-induced apoptosis in DLD-1 cells. This is evident from the fact that the p53/55 proform of caspase-8 becomes not processed into its enzymatic active subunits during p53-induced apoptosis. The lack of caspase-8 activation is not caused by a defect in this molecule as TRAIL and FasL eciently induce caspase-8 processing within 3 h (Figure 2b ). In accordance with a death receptor-independent mode of p53-induced apoptosis, we found in no experiment an upregulation of the death ligand FasL (Figure 3a ) and only occasionally a modest upregulation of the death ligand TRAIL (Table  1) . It should be noted that the lack of evidence for a role of death receptors in p53-induced apoptosis in DLD-1 cells is not related to death receptor antagonizing pathways (e.g. NF-kB) as exogenously added TRAIL or FasL induced rapid cell death in the absence (Figure 2b ) as well as in the presence of 53 (data not shown). A role of death receptor-induced caspase-10 activation in p53-induced cell death can not be absolutely ruled out, but this seems very unlikely as we (i) were unable to detect caspase-10 mRNA by RNAse protection assay analysis (data not shown) and (ii) there is no obvious explanation why caspase-10 but not caspase-8 should be activated by death receptors. While there is no evidence for a contribution of death receptor-induced apoptosis, the experimental data match well with a mitochondrial pathway of p53-induced apoptosis. In this respect, we found upregulation of the proapoptotic bcl-2 family members Bik and Bak and concomitantly inhibition of Bcl-x L expression ( Figure 3b ). In accordance with Bik/Bak-induced apoptosis, we found that caspase-9 activation preceded caspase-3 processing (Figure 2b ). During our systematic analysis of the impact of p53 on apoptosis-related genes, we found unexpectedly that cFLIP a potent inhibitor of death receptor became upregulated upon p53-induction in DLD-1 cells (Figures 3c and 4a ). This is of particular interest since two recent reports even point to FLIP as tumor progression factor (Medema et al., 1999; Djerbi et al., 1999) . As already discussed above induction of p53 and therefore up-regulation of cFLIP had no signi®cant impact on apoptosis induced by exogenous TRAIL and FasL. At the ®rst glance this is contradictory to the well-documented death receptor inhibitory capability of FLIP. However, it has to be taken into consideration that FLIP act in a stoichiometric way to inhibit formation of death-inducing signaling complexes of Fas and/or TRAIL-R1/2. Thus, even p53-upregulated FLIP levels in DLD-1 cells may fail to inhibited death receptor-mediated caspase-8 activation completely. In particular as these receptors are also up-regulated by p53 in the DLD-1 model. Nevertheless, FLIP is an interesting anti-apoptotic target of p53 that may have a critical role in other cell lines. In particular, in cell lines which do not respond with apoptosis towards induction of p53. Ryan et al. (2000) have recently shown that p53-induced apoptosis is essentially dependent on the p53-mediated activation of NF-kB. However, in other experimental systems, opposite results have been obtained, showing an inhibition of NF-kB activation by p53 (Webster and Perkins, 1999) , or inactivation of p53 by NF-kB (Pise-Masison et al., 2000) . These Figure 5 p53-wt does not activate NF-kB in DLD-1 cells but inhibit TNF-induced NF-kB activation. (a) p53-wt was induced for the indicated time and as a control one group was treated with TNF (20 ng/ml) for 30 min. Cells were harvested and analysed for NF-kB activation by EMSA. (b) DLD-1-p53wt and DLD-1-p53mut were cultivated in 96-well tissue culture plates and transiently transfected with a 36NF-kB-luciferase reporter plasmid along with a SV40 promoter-driven b-galactosidase expression plasmid to normalize transfection eciencies. Next day doxycycline was removed for the indicated times and cells were stimulated for additional 4 h with TNF (20 ng/ml, ®lled bars) or remained without further treatment (open bars) and assayed for NF-kB activation. (c) DLD-1-p53wt and DLD-1-p53mut cells were induced for 9 h or remained uninduced and subsequently cells were incubated for additional 3 h in the presence or absence of TNF (20 ng/ml). Total RNAs were prepared and probed with the hApo-5 Multi Probe template set by RPA analysis to detect TNF-induced genes including the well-known NF-kB-dependent cIAP2 gene. results are consistent with a recent study proposing interference of p53 and NF-kB by competing for a limiting pool of the transcriptional coactivator proteins p300 and CREB-binding protein (Webster and Perkins, 1999) . Besides p53-induced activation of NF-kB (Ryan et al., 2000) , the reciprocal process, namely induction of p53 by NF-kB, has also been described (Uberti et al., 2000; Benoit et al., 2000) . Thus, it seems possible that the NF-kB and p53 pathways may be crossregulated at several levels in a cell type speci®c manner. In DLD-1 cells we found no evidence for p53-mediated NF-kB activation (Figure 5 ), neither in EMSA analyses nor in reporter gene assays. In particular, we found no up-regulation of IAP2 which is often stimulated via NF-kB. However, in agreement with Webster and Perkins we found a clear inhibition of NF-kB activation upon induction of p53 ( Figure 5) .
In summary, our data show that in DLD-1 cells induction of apoptosis occurs independent of NF-kB and caspase-8 activation, and we suggest an involvement of the apoptotic mitochondrial pathway. Studies are ongoing to elucidate whether p53-induced NF-kB activation is part of the p53-dependent apoptotic pathway in other cell systems. Similarly, it will be important to determine if the p53-induced up-regulation of death domain-containing receptors and/or their negative regulator cFLIP can play a critical role in determination of cellular sensitivity against p53 activation.
Materials and methods

Cell culture
DLD-1 cells stably transfected with tetracycline-regulated p53-wt (DLD-1-p53wt) and p53-R175H (DLD-1-p53mut) were a kind gift from Bert Vogelstein (Johns Hopkins University, Baltimore, USA) and were cultured in McCoy's 5A medium (GIBCO BRL, Eggenstein, Germany) supplemented with 10% heat-inactivated fetal calf serum, 2 mM glutamine, 400 mg/ml G418, 250 mg/ml hygromycin B and 50 ng/ml doxycycline (Invitrogen), in a 5% CO 2 atmosphere at 378C. p53-wt and p53-R175H were induced by exchange of the doxycycline-containing medium with doxycycline-free medium. HEK293 cells were maintained in RPMI 1640 medium containing 5% heat-inactivated fetal calf serum.
Cell death assays
DLD-1 cells were cultivated in 96-well microtiter plates (1.5610 4 per well) or 100 mm plates (2610 6 ) overnight. Next day apoptosis was induced by removal of doxycycline or treatment with Flag-tagged TRAIL or FasL cross-linked with the anti-Flag mAb M2 (Sigma, Deisenhofen, Germany). After the indicated times metabolic activities were measured by the MTT method or lysates were prepared for immunoblot analysis.
RNAse protection assay
Expression of p53-wt and p53-R175H in DLD-1-p53wt and DLD-1-p53mut, respectively, were induced in 10 7 cells by removal of doxycycline. After the indicated times, total RNA was isolated with the pegGOLDRNA pure kit (PEQlab, Erlangen, Germany) according to the manufacturer's recommendations. The presence of transcripts of the indicated apoptosis-related genes, as well as L32 and GAPDH as internal controls, were analysed using the hApo2, hApo3b, hApo3c, hApo6 and hStress-1 Multi-Probe template sets (BD PharMingen, Heidelberg, Germany). Probe synthesis, hybridization and RNase treatment were performed with the RiboQuant Multi-Probe RNase Protection Assay System (BD PharMingen, Heidelberg, Germany) according to the manufacturer's recommendations. Protected transcripts were analysed by denaturing polyacrylamide gel electrophoresis on 5% acrylamide gels and quanti®ed on a PhosphorImager with the ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA). To correct signals of protected transcripts for background intensities, the latter were determined for each individual band in close neighborhood to the mRNA-signal of interest and subtracted from the value of the protected transcript.
Western blotting
Cell lysates were prepared in RIPA buer supplemented with 5% (v/v) of a protease inhibitor cocktail stock solution (Boehringer) and proteins were separated by SDS ± PAGE. Upon electroblotting to nitrocellulose membranes, nonspeci®c binding sites were blocked by incubation in blocking solution (TBS, 0.05% Tween-20, 3% (w/v) dry milk) and p53, caspase-2, -3, -8, -9 and cFLIP were detected with antip53 mAb DO-1 (Santa Cruz), anti-caspase-2 mAb 35 (Pharmingen, Heidelberg, Germany) anti-caspase-3 mAb clone 19 (Transduction Laboratories, Heidelberg, Germany), anti-caspase-8 (a kind gift from Klaus Schulze-Ostho, University of TuÈ bingen, Germany), anti-caspase-9 mAb Ab-2 (Calbiochem, Schwalbach, Germany) and anti-FLIP mAb N19 (a gift from Ingo Schmitz and Peter Krammer, DKFZ Heidelberg, Germany). Bound primary antibodies were ®nally visualized with alkaline phosphatase-conjugated goat anti-mouse-IgG (Sigma, Deisenhofen, Germany) and goat anti-rabbit-IgG, respectively (Roche Molecular Biochemicals, Mannheim, Germany).
Characterization and molecular cloning of the 5'-upstream sequence of the known cFLIP cDNA sequence For identi®cation of putative promoter elements upstream of the known 5' end of FLIP cDNA, we utilized a commercially available PCR based DNA walking approach (GenomeWalker Kit, human, Clontech, Heidelberg, Germany) according to the manufacturer's recommendations. For the two PCR ampli®-cation steps involved, antisense primers corresponding to position 66 to 95 (R95 5'-CTC AGC TGT CAC TGG ACA AAA GTC CAA-3') and 115 to143 (R143 5'-CTG TTC GCG GCG CTT CTC TCC TAC ACC-3') of the known FLIP/ Caspaser cDNA (accession number AF010127) were used. A 0.9 kb fragment was obtained this way and cloned into pTOPO (Invitrogen, Groningen, Netherlands). To allow reporter gene studies, this fragment was cleaved out from pTOPO using the HindIII and XbaI site of the vector and inserted into the HindIII and NheI site of pGL3-Basic resulting in pGL3-FLIP-pro (Promega, Mannheim, Germany).
NF-kB-and FLIP promoter reporter gene assays
For monitoring p53-dependent activity of pGL3-FLIP-pro in transiently transfected 293 cells, cells (2610 4 per well) were seeded in 96-well tissue culture plates and the following day the cells were transfected with the indicated combinations (together 220 ng/well) of pGL3-FLIP-pro, pGL3-basic, pCMVhump53 and pCMVp53Ser249 along with a SV40 promoter-driven b-galactosidase expression plasmid (30 ng/ well) to normalize the transfection eciency. Transfections were performed with SuperFect reagent according to the manufacturer's recommendations (Qiagen, Hilden, Germany). After 1 day of recovery, the cells were harvested in PBS, lysed in luciferase lysis buer (Promega, Mannheim, Germany) and ®nally luciferase and b-galactosidase activities were determined using a Lucy2 96-well luminometer (Anthos, Krefeld, Germany). Analysis of pGL3-FLIP-pro activity in DLD-1-p53wt and DLD-1-p53mut cells, respectively, were performed as follows: 10 6 cells were seeded in 6 cm cell culture petri dishes and transfected next day with 10 mg of DNA (9 mg pGL3-FLIP-pro or pGL3-basic, respectively, and 1 mg b-galactosidase) with SuperFect (Qiagen, Hilden, Germany). The transfection mixture was returned after 3 h and cells were recovered overnight. Next day cells were split into a 96-well tissue culture plate (30610 3 /well) cultivated again over night and were then induced for p53-induction as indicated. The activity of a NF-kB-driven reporter gene was analysed as described already for pGL3-FLIP-pro with a 36NF-kB-luciferase reporter plasmid.
EMSA analysis of NF-kB activation
DLD-1-p53wt and DLD-1-p53mut cells (10 6 ) were seeded in 60 mm cell culture dishes and cultured overnight to allow adherence. Next day the cells were treated as indicated with doxycycline-free medium for the induction of p53 and with TNF to engage the NF-kB pathway. Nuclear extracts were prepared as described elsewhere (Dignam et al., 1983) and EMSA analyses were performed using a standard procedure with a HPLC-puri®ed NF-kB-speci®c oligonucleotide (5'-ATC AGG GAC TTT CCG CTG GGG ACT TTC CG-3'), end-labeled with g-32 P-ATP. Finally, NF-kB DNA-binding activity was analysed by native PAGE and phospho-imaging (Storm 860; Amersham Pharmacia Biotech, Freiburg, Germany).
Abbreviations EMSA, Electrophoretic mobility shift assay; FLIP, FLICE-inhibitory protein; RPA; RNase protectin assay; NF-kB, nuclear factor kB; TRAIL-R1/2, TNF-related apoptosis-inducing ligand (TRAIL) receptor 1/2; TNF, tumor necrosis factor.
